Iterum Therapeutics plc (ITRMF) Share-based Compensation (2017 - 2025)

Iterum Therapeutics has reported Share-based Compensation for 9 years, with the latest figure at $940664.0 in Q3 2025.

• On a quarterly basis, Share-based Compensation rose 2.92% year-over-year to $940664.0 in Q3 2025; TTM through Sep 2025 was $940664.0, a 2.92% increase from a year earlier, with the FY2024 full-year figure at $841720.0, down 24.58% from the prior year.
• Share-based Compensation was $940664.0 for Q3 2025 at Iterum Therapeutics, up from $760906.0 in the prior quarter.
• The five-year high for Share-based Compensation was $25.7 million in Q2 2021, with the low at $89000.0 in Q4 2024.
• Average Share-based Compensation over 5 years is $5.3 million, with a median of $1.1 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation jumped 2249.28% in 2022, then plunged 92.86% in 2023.
• Over 5 years, Share-based Compensation stood at $2.0 million in 2021, then sank by 76.77% to $457000.0 in 2022, then tumbled by 69.58% to $139000.0 in 2023, then slumped by 35.97% to $89000.0 in 2024, then soared by 956.93% to $940664.0 in 2025.
• The last three Share-based Compensation figures came in at $940664.0 (Q3 2025), $760906.0 (Q2 2025), and $834227.0 (Q1 2025), per Business Quant data.